It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

Using CRISPR, the popular gene-editing tool, scientists bumped up the fruit’s sugar content by 30 percent without sacrificing ...

EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report), ...

Glucose and fructose levels were 30 per cent higher after researchers removed two genes that regulate sugar content, ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

In this study, the investigators used the CRISPR gene editing tool to delete various genetic sequences, and identified about ...

The global animal model market is expected to grow from USD 1,943.3 million in 2024 to USD 3,476.8 million by 2034, at a CAGR ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.